Loading…
A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method
A simple method for the quantification of tipranavir, the first non-peptidic HIV protease inhibitor, was developed and validated. Quinoxaline, as internal standard, was added to 50 μl of plasma before a liquid–liquid extraction by 600 μl of protein precipitation solution. The extracts were diluted b...
Saved in:
Published in: | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Analytical technologies in the biomedical and life sciences, 2007-04, Vol.848 (2), p.374-378 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | A simple method for the quantification of tipranavir, the first non-peptidic HIV protease inhibitor, was developed and validated. Quinoxaline, as internal standard, was added to 50
μl of plasma before a liquid–liquid extraction by 600
μl of protein precipitation solution. The extracts were diluted before being injected in the chromatographic system. Chromatographic separation was made on a C18 column using potassium phosphate buffer (pH 3.2) and acetonitrile with gradient. Detection was performed by an UV detector at 260
nm. Relative error at three control quality concentrations ranged from −1.81 to 1.72%. Intra-day (CV%) and inter-day (CV%) precision ranged from 0.94 to 2.55% and from 3.07 to 4.24%, respectively. LOQ and LOD were 0.090
μg/ml and 0.035
μg/ml, respectively. Mean recovery was 87.1%
±
2.4%. Calibration curve was linear up to 180
μg/ml. Concentration range when optimized (0.703–180
μg/ml) proved to be adequate to measure tipranavir concentration in HIV-1-positive patients, therefore this method could be suitable for therapeutic drug monitoring of this drug. |
---|---|
ISSN: | 1570-0232 1873-376X |
DOI: | 10.1016/j.jchromb.2006.10.030 |